RVX-208: Phase II data

Top-line data from the double-blind, U.S. Phase II ASSERT trial in 299 patients showed that once-daily 300 mg RVX-208 plus standard of care (SOC) consisting of the physician's choice of statin therapy missed the primary endpoint of significantly increasing APOA1 from baseline to week 12 vs. placebo plus SOC (5.6% vs. 0.9%, p=0.06). Resverlogix said that RVX-208 did lead to dose-dependent increases in APOA1 (p=0.035). On secondary endpoints, high-dose RVX-208 significantly increased HDL-C (8.3% vs. 0%, p<0.01) and large-particle HDL (21.1% vs. 0%, p<0.001) from baseline to week 12 vs. placebo. ...